| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Delcasertib targets the δ isoform of protein kinase C (δPKC), a key mediator of cell death and inflammation during ischemia‑reperfusion. By selectively inhibiting δPKC, it blocks pro‑apoptotic signalling without affecting other PKC isoforms, thereby reducing myocardial damage.
|
|---|---|
| ln Vitro |
Delcasertib (KAI-9803) is composed of an 11-amino acid cell-penetrating peptide, HIV type 1 transactivator protein (TAT47-57; referred to as the "carrier peptide"), which is a selective inhibitory peptide of delta-protein kinase C (δPKC) that is derived from the deltaV1-1 moiety of deltaPKC and reversibly conjugated to a peptide that is reversibly conjugated to a cell-penetrating peptide [1].
In vitro, delcasertib selectively inhibits δPKC activity in cell‑free kinase assays; it shows no significant inhibition of other PKC isoforms. Its peptide nature ensures high specificity. In cellular models, it protects cardiomyocytes from hypoxia‑reoxygenation injury by preventing δPKC‑mediated mitochondrial dysfunction. |
| ln Vivo |
In mouse liver, kidney, lung, heart, and brain, delcasertib (KAI-9803, single intraperitoneal injection) specifically inhibits PKC translocation [1]. Research has indicated that administering Delcasertib (KAI-9803) towards the end of ischemia can lessen the damage that ischemia-reperfusion causes to the heart in a rat model of acute myocardial infarction [1]. Patients having angioplasty following an acute myocardial infarction have been examined for the prevention of reperfusion injury with delcasertib (KAI-9803) [2].
In vivo, delcasertib reduces infarct size and improves cardiac function in animal models of acute myocardial infarction when administered before or during reperfusion. It has shown efficacy in preclinical studies, supporting its potential as a cardioprotective agent. |
| Enzyme Assay |
δPKC inhibitory activity is measured in cell‑free kinase assays using recombinant δPKC, a peptide substrate, and ATP; phosphorylation is quantified, and IC50 is derived. Selectivity is confirmed by testing against other PKC isoforms.
|
| Cell Assay |
Cell‑based assays use cardiomyocyte cell lines subjected to simulated ischemia‑reperfusion; delcasertib is added to assess cell viability (MTT/LDH), mitochondrial membrane potential, and apoptosis markers, confirming cytoprotection.
|
| Animal Protocol |
Animal/Disease Models: Sixweeks old male Crl:CD(SD) rats [1].
Doses: 1 mg/kg (pharmacokinetic/PK/PK analysis). Route of Administration: Through the femoral vein. Experimental Results: Reversible conjugation to TAT47-57 promoted distribution to tissues such as liver, kidney, and heart. In vivo studies involve rodent models of myocardial infarction with reperfusion; delcasertib is given intravenously at the time of reperfusion. Infarct size, cardiac enzymes, and functional parameters are measured to evaluate cardioprotection. |
| ADME/Pharmacokinetics |
Delcasertib is a peptide, thus likely administered parenterally; its half‑life is short, typical of peptides. Detailed PK data (clearance, volume of distribution) are not fully public, but its efficacy in acute settings suggests rapid action.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data are available; as a peptide, immunogenicity and injection site reactions are potential risks. Its selective inhibition of δPKC may avoid off‑target toxicities, but safety studies are needed for clinical use.
|
| References |
|
| Additional Infomation |
Drug Indication
It has been studied for the treatment of myocardial infarction. Delcasertib is an investigational compound not approved; studied for acute myocardial infarction. Its selective δPKC inhibition provides a targeted approach to reduce reperfusion injury, but clinical trials have not led to approval, possibly due to efficacy or safety challenges. |
| Molecular Formula |
C120H199N45O34S2
|
|---|---|
| Molecular Weight |
2880.27518010139
|
| Exact Mass |
2879.47
|
| CAS # |
949100-39-4
|
| Related CAS # |
Delcasertib hydrochloride
|
| PubChem CID |
56843747
|
| Appearance |
White to off-white solid powder
|
| LogP |
-19.7
|
| Hydrogen Bond Donor Count |
53
|
| Hydrogen Bond Acceptor Count |
46
|
| Rotatable Bond Count |
108
|
| Heavy Atom Count |
201
|
| Complexity |
6270
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
S(C[C@@H](C(N[C@@H](CC1C=CC(=CC=1)O)C(NCC(N[C@@H](CCCNC(=N)N)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCCN)=O)=O)=O)=O)N)SC[C@@H](C(N[C@@H](CO)C(N[C@@H](CC1C=CC=CC=1)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC1C=CC(=CC=1)O)C(N[C@@H](CCC(=O)O)C(N[C@H](C(NCC(N[C@@H](CO)C(N[C@H](C(=O)O)CC(C)C)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)N
|
| InChi Key |
XPXZTVWPRKJTAA-PJKOMPQUSA-N
|
| InChi Code |
InChI=1S/C120H199N45O34S2/c1-61(2)48-80(96(179)145-55-92(174)148-86(56-166)110(193)163-85(114(198)199)49-62(3)4)159-106(189)78(37-39-93(175)176)156-107(190)83(52-65-30-34-67(170)35-31-65)161-112(195)88(58-168)165-109(192)84(53-90(126)172)162-108(191)82(50-63-18-6-5-7-19-63)160-111(194)87(57-167)164-95(178)69(124)60-201-200-59-68(123)94(177)158-81(51-64-28-32-66(169)33-29-64)97(180)146-54-91(173)147-70(22-12-42-139-115(127)128)98(181)149-71(20-8-10-40-121)99(182)150-72(21-9-11-41-122)100(183)151-73(23-13-43-140-116(129)130)101(184)152-75(25-15-45-142-118(133)134)103(186)155-77(36-38-89(125)171)105(188)154-74(24-14-44-141-117(131)132)102(185)153-76(26-16-46-143-119(135)136)104(187)157-79(113(196)197)27-17-47-144-120(137)138/h5-7,18-19,28-35,61-62,68-88,166-170H,8-17,20-27,36-60,121-124H2,1-4H3,(H2,125,171)(H2,126,172)(H,145,179)(H,146,180)(H,147,173)(H,148,174)(H,149,181)(H,150,182)(H,151,183)(H,152,184)(H,153,185)(H,154,188)(H,155,186)(H,156,190)(H,157,187)(H,158,177)(H,159,189)(H,160,194)(H,161,195)(H,162,191)(H,163,193)(H,164,178)(H,165,192)(H,175,176)(H,196,197)(H,198,199)(H4,127,128,139)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)/t68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid
|
| Synonyms |
KAI-9803; BMS-875944; KAI 9803; BMS 875944; KAI9803; BMS875944
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~34.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.69 mg/mL (2.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 76.9 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3472 mL | 1.7359 mL | 3.4719 mL | |
| 5 mM | 0.0694 mL | 0.3472 mL | 0.6944 mL | |
| 10 mM | 0.0347 mL | 0.1736 mL | 0.3472 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA